James McArthur, PhDCEO and President at PepGen
Profile
James McArthur currently serves as President and Chief Executive Officer of PepGen and serves on the company’s Board of Directors. James has 30 years of industry experience, has cofounded 5 biotechnology companies, 3 of which were acquired, and has served as a Director of two companies through successful initial public offerings. He was founding CEO of Imara, a public company developing therapies for sickle cell disease and beta-thalassemia, co-founder and President of R&D of Cydan, a rare disease accelerator, and founding CSO of Synovex/Adheron, a rheumatology therapy company acquired by Roche. Prior to these companies, James held senior research leadership roles in several pioneering gene and stem cell therapy companies. He was a Venture Partner at RA Capital and an entrepreneur in residence at HealthCare Ventures. James was previously a post-doctoral fellow at MIT and UC Berkeley working with Drs. David Raulet and Nobel Laureate James Allison, before which he received his PhD in molecular oncology and BSc in biochemistry from McGill University in Montreal.
Agenda Sessions
EDO Peptide Delivery of Exon 51 Skipping Oligonucleotide in Healthy Volunteers
, 08:45View Session